SEC FORM 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:		3235-0287
Expires:	December 31, 2014
Estimated average burden
hours per response:		0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person ^*

ARCH Venture Fund X, L.P.

(Last)

(First)

(Middle)

8755 W. HIGGINS ROAD, SUITE 1025

(Street)

CHICAGO

60631

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Aspen Neuroscience, Inc. [ ASPE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/02/2026		P		66,666	A	$ 15	66,666	D ⁽¹⁾ ⁽²⁾
Common Stock	11/02/2026		C		187,182	A	⁽³⁾	253,848	D ⁽¹⁾ ⁽²⁾
Common Stock	11/02/2026		C		298,258	A	⁽³⁾	552,106	D ⁽¹⁾ ⁽²⁾
Common Stock	11/02/2026		C		286,304	A	⁽³⁾	838,410	D ⁽¹⁾ ⁽²⁾
Common Stock	11/02/2026		C		295,490	A	⁽³⁾	1,133,900	D ⁽¹⁾ ⁽²⁾
Common Stock	11/02/2026		C		259,948	A	⁽³⁾	1,393,848	D ⁽¹⁾ ⁽²⁾
Common Stock	11/02/2026		P		66,667	A	$ 15	66,667	D ⁽²⁾ ⁽⁴⁾
Common Stock	11/02/2026		C		298,258	A	⁽³⁾	364,925	D ⁽²⁾ ⁽⁴⁾
Common Stock	11/02/2026		C		286,304	A	⁽³⁾	651,229	D ⁽²⁾ ⁽⁴⁾
Common Stock	11/02/2026		C		295,490	A	⁽³⁾	946,719	D ⁽²⁾ ⁽⁴⁾
Common Stock	11/02/2026		C		214,355	A	⁽³⁾	1,161,074	D ⁽²⁾ ⁽⁴⁾
Common Stock	11/02/2026		P		1,200,000	A	$ 15	1,200,000	I	See Footnote ⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series Seed Convertible Preferred Stock	⁽³⁾	11/02/2026		C			187,182	⁽³⁾	⁽³⁾	Common Stock	187,182	⁽³⁾	0	D ⁽¹⁾ ⁽²⁾
Series A-1 Convertible Preferred Stock	⁽³⁾	11/02/2026		C			298,258	⁽³⁾	⁽³⁾	Common Stock	298,258	⁽³⁾	0	D ⁽¹⁾ ⁽²⁾
Series A-1 Convertible Preferred Stock	⁽³⁾	11/02/2026		C			298,258	⁽³⁾	⁽³⁾	Common Stock	298,258	⁽³⁾	0	D ⁽²⁾ ⁽⁴⁾
Series A-2 Convertible Preferred Stock	⁽³⁾	11/02/2026		C			286,304	⁽³⁾	⁽³⁾	Common Stock	286,304	⁽³⁾	0	D ⁽¹⁾ ⁽²⁾
Series A-2 Convertible Preferred Stock	⁽³⁾	11/02/2026		C			286,304	⁽³⁾	⁽³⁾	Common Stock	286,304	⁽³⁾	0	D ⁽²⁾ ⁽⁴⁾
Series B Convertible Preferred Stock	⁽³⁾	11/02/2026		C			295,490	⁽³⁾	⁽³⁾	Common Stock	295,490	⁽³⁾	0	D ⁽¹⁾ ⁽²⁾
Series B Convertible Preferred Stock	⁽³⁾	11/02/2026		C			295,490	⁽³⁾	⁽³⁾	Common Stock	295,490	⁽³⁾	0	D ⁽²⁾ ⁽⁴⁾
Series C Convertible Preferred Stock	⁽³⁾	11/02/2026		C			259,948	⁽³⁾	⁽³⁾	Common Stock	259,948	⁽³⁾	0	D ⁽¹⁾ ⁽²⁾
Series C Convertible Preferred Stock	⁽³⁾	11/02/2026		C			214,355	⁽³⁾	⁽³⁾	Common Stock	214,355	⁽³⁾	0	D ⁽²⁾ ⁽⁴⁾

Explanation of Responses:

1. Securities held by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.

2. ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen (collectively, the "AVP X Committee Members") comprise the investment committee of AVP X LLC. AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members disclaims beneficial ownership except to the extent of any pecuniary interest therein.

3. Each share of Series Seed Convertible Preferred Stock, Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-9.8821 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.

4. Securities held by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.

5. Shares were purchased by ARCH Venture Fund XIV, L.P. ("ARCH XIV"). The AVP X Investment Committee Members also are members of the investment committee for ARCH XIV.

Remarks:

This Form 4 is one of two reports being filed jointly by ARCH X, AVP X LP, ARCH X Overage, AVP X Overage LP, AVP X LLC, Robert Nelsen, Steven Gillis, Keith Crandell, Kristina Burow, ARCH XIV, ARCH Venture Partners XIV, L.P., ARCH Venture Partners XIV, LLC, and Paul Berns (collectively, the "Reporting Persons").

	ARCH Venture Fund X, L.P. By: ARCH Venture Partners X, L.P., its General Partner By: ARCH Venture Partners X, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact	11/02/2026
	** Signature of Reporting Person	Date
	ARCH Venture Fund X Overage, L.P. By: ARCH Venture Partners X Overage, L.P., its General Partner By: ARCH Venture Partners X, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact	11/02/2026
	** Signature of Reporting Person	Date
	ARCH Venture Partners X, L.P. By: ARCH Venture Partners X, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact	11/02/2026
	** Signature of Reporting Person	Date
	ARCH Venture Partners X Overage, L.P. By: ARCH Venture Partners X, LLC, its General Partner By: /s/ Mark McDonnell, as Attorney-in-Fact	11/02/2026
	** Signature of Reporting Person	Date
	ARCH Venture Partners X, LLC By: /s/ Mark McDonnell, as Attorney-in-Fact	11/02/2026
	** Signature of Reporting Person	Date
	/s/ Robert Nelsen, By: Mark McDonnell, as attorney-in-fact	11/02/2026
	** Signature of Reporting Person	Date
	/s/ Keith Crandell, By: Mark McDonnell, attorney-in-fact	11/02/2026
	** Signature of Reporting Person	Date
	/s/ Kristina Burow, By: Mark McDonnell, attorney-in-fact	11/02/2026
	** Signature of Reporting Person	Date
	/s/ Steven Gillis, By: Mark McDonnell, attorney-in-fact	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.